Exploiting vulnerable biology for malaria drug discovery

Value of the Information & Strength of the Argument

The talk provides valuable insights into the drug discovery process for malaria, highlighting both phenotypic and target-based approaches. The argumentation is solid, supported by experimental data, including resistance selection, structural biology, and medicinal chemistry optimization. The speaker effectively demonstrates the importance of understanding parasite biology and leveraging structural information to design selective inhibitors. The presentation is well-structured, with clear explanations of the rationale behind each step.

Scientific Rigor, Source Quality, Title Accuracy

The speaker is a recognized expert, and the talk references published work, including a Cell Chemical Biology paper and a J. Med. Chem. paper. The title accurately reflects the content. The talk is a conference presentation, so it is not peer-reviewed, but the methods and results are presented with sufficient detail to assess their rigor. The description provides links to additional resources, but no external sources are cited within the talk itself.

The title accurately reflects the content, which focuses on exploiting vulnerable biology of malaria parasites for drug discovery.

8/10

The talk is delivered by a leading expert in the field, with detailed descriptions of experimental methods and results, including references to published work. However, it is a conference presentation and not a peer-reviewed publication, and some claims are not fully detailed.

Markers derived by PSI from the transcript: the creator did not define chapters.

• 02:00Introduction to malaria burden and drug resistance challenges.
• 05:00Overview of Plasmodium life cycle and therapeutic goals.
• 10:00Phenotypic screening approach and identification of S042 series.
• 15:00Target identification via resistance selection and whole-genome sequencing.
• 20:00Cryo-EM structure of proteasome inhibitor complex and novel binding site.
• 25:00Target-based approach: DHODH as a druggable target.
• 30:00Development of DSM265 and its clinical validation.
• 35:00Scaffold hop to pyrrolopyridinones and lead optimization.
• 40:00Final compound 1465 with predicted long half-life.

• ASBMB Annual Meeting Proposals — Call for proposals for the 2027 ASBMB Annual Meeting.
• Chemistry meets biology to thwart parasites — Article about Margaret Phillips' research.

• Cell Chemical Biology paper on proteasome inhibitors — Published work from the lab on the proteasome inhibitor series.
• J. Med. Chem. paper on DHODH inhibitors — Published work on the pyrrolopyridinone series.